


Model Validation


Dave Glidden
3 December 2013

ROC Lee Model: Learn




Area under ROC curve = 0.8405

ROC: Test



Density



Calibration

- Model: predicted probability
- Does predicted probability match truth
- Important for individual decision making
- Classic model-checking problem
- Incorporate statistical tests and descriptions of magnitude
- Find model misspecified in some way

Lee Model validation set

```
. xi: logistic dead i.agecat male hrsdm hrsca hrslung hrschf bmi smoke bath money walkjog push  
i.agecat      _Iagecat_0-6      (naturally coded; _Iagecat_0 omitted)
```

```
Logistic regression              Number of obs   =       7973  
                                LR chi2(17)      =      1413.63  
                                Prob > chi2       =       0.0000  
Log likelihood = -2423.8528      Pseudo R2      =       0.2258
```

dead	Odds Ratio	Std. Err.	z	P> z	[95% Conf. Interval]	
-----+-----						
_Iagecat_1	1.537822	.2259016	2.93	0.003	1.1531	2.050903
_Iagecat_2	2.248315	.3291624	5.53	0.000	1.687476	2.995549
_Iagecat_3	2.586506	.381196	6.45	0.000	1.937602	3.45273
_Iagecat_4	4.109389	.5813912	9.99	0.000	3.114228	5.422558
_Iagecat_5	7.608406	1.14937	13.43	0.000	5.658564	10.23013
_Iagecat_6	14.62968	2.233807	17.57	0.000	10.84588	19.73353
male	2.166964	.1712289	9.79	0.000	1.856058	2.529949
hrsdm	1.761092	.1639891	6.08	0.000	1.467303	2.113704
hrsca	1.664218	.1689592	5.02	0.000	1.36393	2.030617
hrslung	1.587757	.2179521	3.37	0.001	1.213219	2.07792
hrschf	2.136519	.3437415	4.72	0.000	1.558685	2.928569
bmicat	1.736036	.1361793	7.03	0.000	1.488635	2.024553
smoke	1.594206	.1606953	4.63	0.000	1.308409	1.942429
bath	1.474593	.1711166	3.35	0.001	1.174616	1.851179
money	1.420027	.1534369	3.25	0.001	1.149006	1.754974
walkjog	1.995648	.1817115	7.59	0.000	1.66947	2.385553
push	1.49066	.1350732	4.41	0.000	1.248098	1.780363
-----+-----						

Inspecting Calibration

- Form series of groups based on risk
 - Compare expected mortality with observed
 - Expected: `average(probs)`
 - Observed: `average(death)`
= *proportion who died*
 - Within each group
- our point total furnishes such a group

Test Set

```
. table pts2 if valid==0, c(n dead mean dead mean prob)
```

Points		N	mean(dead)	mean(prob)

0		486	.0041152	.0073689
1		739	.0067659	.0126751
2		1,366	.0095168	.017859
3		1,474	.0325645	.0277967
4		1,445	.0394464	.0407945
5		1,330	.0503759	.0589664
6		1,162	.0886403	.0849856
7		886	.1230248	.1186558
8		758	.1912929	.1653885
9		551	.2413793	.2242661
10		407	.2727273	.2922267
11		320	.43125	.384265
12		244	.4836065	.4604374
13		174	.5344828	.5641574
14		107	.5046729	.6368158
15+		203	.7438424	.7780437

Validation Set


```
. table pts2 if valid==1, c(n dead mean dead mean prob)
```

Points	N	mean(dead)	mean(prob)
0	354	.0056497	.0073689
1	489	.0204499	.0127029
2	889	.0168729	.0174934
3	971	.0360453	.0275617
4	986	.0598377	.0408728
5	842	.0771971	.0585236
6	758	.0936675	.0851236
7	637	.1507064	.1188091
8	498	.1967871	.1658374
9	401	.19202	.2229141
10	308	.275974	.2988213
11	232	.4568965	.3782594
12	192	.4427083	.4634854
13	159	.591195	.5602076
14	77	.5584416	.6408411
15+	180	.6777778	.789714

Smoothing

- Alternative graphical approach
- Draw smooth curve of mortality by predicted probability
- Should look like straight line
- Assessed in test and validation set

Smoothed Calibration



Summary

- See classic overfitting pattern
 - mortality lower than pred at high end
 - mortality higher than pred at low end
- Large calibrations at high end
 - represent 5% of the prediction
 - fixing would complicate model

Validation

- Calibration: examination of model spec
 - largely internal
- Discrimination: measure separation
 - largely external
- Calibration can be fixed
- Discrimination dictates utility of model

Examining Improvement in Risk Prediction

Risk Model

- Existing set of risk factors for disease
- Novel marker or test
genetic, proteomic, imaging, biomarker
- New marker add predictive information
- How much better are predictions?
do they aid in clinical decision making

Examples

- Breast density for breast cancer risk
Tice et al. 2008
- C-reactive protein for CV risk
Cook et al. 2006
- PSA for prostate cancer risk

The Easy Question

and least interesting

- Statistically significant contribution?
- Fit a logistic/Cox regression model
- Examine p-value for new measure
adjusting for other factors
- Gives p-value
- Implies better prediction
most compelling in validation data

Why not interesting?

- An easy threshold
- Many factors can reach this
- Statistical significant $\neq$ clinical significance
- Relevant summary needed
on which to gauge clinical implications

Measure of Prediction

- TPF = true positive fraction
proportion of case “positive”
aka: sensitivity
- FPF = false positive fraction
proportion of control “positive”
1-specificity
- Trade-off
- Two kinds of errors
context dependent trade off

Prediction/OR Disconnect

- Potentially misleading measure of predict.
-- odds ratio (OR)
- Moderate to large OR not enough for prediction
- Need a huge odds ratio for a variable to imply good prediction

Odds Ratio of 3.0

Test

Disease

	+	-	
+	90	10	100
-			900
			1000

OR = 3.0

Sens = 0.90

Odds Ratio of 3.0

Test

Disease

	+	-	
+	90	10	100
-	675	225	900
	765	235	1000

OR = 3.0

Sens = 0.90

PVP = 0.12

Spec = 0.25

Odds Ratio of 36.0

Test

Disease

	+	-	
+	90	10	100
-			900
			1000

OR = 36.0

Sens = 0.90

Odds Ratio of 36.0

Test

Disease

	+	-	
+	90	10	100
-	720	180	900
	810	235	1000

OR = 36.0

Sens = 0.90

PVP = 0.89

Spec = 0.80

Dist of Marker and OR




FIGURE 2. Probability distributions of a marker, X , in cases (solid curves) and controls (dashed curves) consistent with the logistic model $\log\text{-it}P(D=1|X) = \alpha + \beta X$. It has been assumed that X has a mean of 0 and a standard deviation of 0.5 in controls so that a unit increase represents the difference between the 84th and 16th percentiles of X in controls. The marker is normally distributed, with the same variance in cases. The odds ratio (OR) per unit increase in X is shown.

Am J Epidemiol 2004;159:882–890

ROC Curves

- Two tests graphed =>
FPF v. TPF (varying threshold)
aligned by FPF
- Don't display absolute risk values
- C-statistic doesn't relate to clinical decisions
measure ability to classify

Tice et al 2008

- Breast cancer risk
- SEER data
- age, race/ethnicity, family hx, biopsy hx
- added value of breast density
HR 4.2 (less than 65), 2.2 (65 or older)
statistically significant
- 5 year risk model (Cox model)
- How much does density add to risk assessment?

Examine Risk Strata

- Based on results of a model, calculate risks
- Group risks in context dependent way
Tice: <1%, 1-1.66%, 1.67-2.5%, > 2.5%
- Compare between models
what happens with good predictive model

Without Breast Density

Strata	<1%	1.0-1.66%	1.67-2.5%	> 2.5%
No. Women	215,402	201,972	148,795	63,105
% event	0.7%	1.3%	1.8%	2.9%

With Density

Strata	<1%	1.0-1.66%	1.67-2.5%	> 2.5%
No. Women	249,959	186,106	124,420	68,744
% event	0.7%	1.3%	2%	3.1%

Calibration

- % events by category
- Both models well calibrated
- % events observed falls within expected
- Calibration has subjective aspect
*if model predicts 2% but is really 3%
close enough?*

Net Reclassification

- Compare two prediction models
*one includes extra predictor
like breast density*
- Cross-tabulate risk predictions based on model
- Examine who gets reclassified
- What % and in which direction?

Table 1. Five-Year Risks for Breast Cancer as Predicted by Models That Do and Do Not Include Breast Density*

5-Year Risk from Model without Breast Density	5-Year Risk from Model with Breast Density				Total
	0% to <1%	1% to 1.66%	1.67% to 2.5%	>2.5%	
0% to <1%					
Women, <i>n</i>	176 831	38 500	71	0	215 402
Events, <i>n</i>	1161	415	0	0	1576
Nonevents, <i>n</i>	175 670	38 085	71	0	213 826
Proportion of women with events	0.7	1.1	0.0	–	0.7
1% to 1.66%					
Women, <i>n</i>	64 297	99 456	37 149	1025	201 927
Events, <i>n</i>	526	1328	754	32	2640
Nonevents, <i>n</i>	63 771	98 128	36 395	993	199 287
Proportion of women with events	0.8	1.3	2.0	3.1	1.3
1.67% to 2.5%					
Women, <i>n</i>	8741	45 478	71 309	23 267	148 795
Events, <i>n</i>	74	609	1419	621	2723
Nonevents, <i>n</i>	8667	44 869	69 890	22 646	146 072
Proportion of women with events	0.9	1.3	2.0	2.7	1.8
>2.5%					
Women, <i>n</i>	90	2672	15 891	44 452	63 105
Events, <i>n</i>	0	38	340	1467	1845
Nonevents, <i>n</i>	90	2634	15 551	42 985	61 260
Proportion of women with events	0.0	1.4	2.1	3.3	2.9
Total					
Women, <i>n</i>	249 959	186 106	124 420	68 744	629 229
Events, <i>n</i>	1761	2390	2513	2120	8784
Nonevents, <i>n</i>	248 198	183 716	121 907	66 624	620 445
Proportion of women with events	0.7	1.3	2.0	3.1	1.4

Reclassification Index

breast cancer cases

Include Density

		<1%	1.0-1.66%	1.67-2.5%	> 2.5%
No Dens	<1%	1161	415	0	0
	1.0-1.66%	526	1328	754	32
	1.67-2.5%	74	609	1419	621
	> 2.5%	0	38	340	1467

Reclassification

cases

- Risk strata with density
 - same: 5375 (61%)
 - lower: 1587 (18%)
less predictive direction
 - higher: 1822 (21%)
more predictive direction
- Net reclassification = 21%-18% = 3%
in the more predictive direction
3% = 235/8784

Reclassification Index

non-cases

Include Density

		<1%	1.0-1.66%	1.67-2.5%	> 2.5%
No Dens	<1%	175,670	38,085	71	0
	1.0-1.66%	63,771	98,128	36,395	993
	1.67-2.5%	8,667	44,869	69,890	22,646
	> 2.5%	90	2,634	15,551	42,985

Reclassification

controls

- Risk strata with density
- same: 386,673 (62%)
- lower: 135,882 (22%)
more predictive direction
- higher: 98,190 (16%)
less predictive direction
- Net reclassification = $22\% - 16\% = 6\%$
in the more predictive direction
 $6\% = 37,392/606,455$

Cutpoints and Net Reclassification

- Depends intimately on the cutpoints
- Risk 2.9% (no density) v. 10% (density)
no reclassification – both in high strata
- Is this a bug or is this a feature?
- Some changes may not
50% risk v. 70% risk

Hypothetical Clinical Trial

- Suppose wanted to know public health impact of adding marker
- RCT: standard v. augmented risk assessment
- Outcome: development of disease
- Presupposes that is some intervention

Public Health Impact

- Draws attention to issues which skulk in background in these debates
- If there is no plausible intervention, what is the health value of improved prediction?
- Is there a reasonable threshold for intervention?
- How much could intervention reduce risk in the population?

Breast Density

- Action point: risk of 1.67% over 5 years
risk < 1.67: no intervention
risk ≥ 1.67: intervention
- Intervention: chemoprophylaxis, enhanced screening, ?
- Intervention effect: 50% reduction in risk
- Starting point for a scenario

*Table 1. Five-Year Risks for Breast Cancer as Predicted by Models That Do and Do Not Include Breast Density**

5-Year Risk from Model without Breast Density	5-Year Risk from Model with Breast Density				Total
	0% to <1%	1% to 1.66%	1.67% to 2.5%	>2.5%	
0% to <1%					
Women, <i>n</i>	176 831	38 500	71	0	215 402
Events, <i>n</i>	1161	415	0	0	1576
Nonevents, <i>n</i>	175 670	38 085	71	0	213 826
Proportion of women with events	0.7	1.1	0.0	–	0.7
1% to 1.66%					
Women, <i>n</i>	64 297	99 456	37 149	1025	201 927
Events, <i>n</i>	526	1328	754	32	2640
Nonevents, <i>n</i>	63 771	98 128	36 395	993	199 287
Proportion of women with events	0.8	1.3	2.0	3.1	1.3
1.67% to 2.5%					
Women, <i>n</i>	8741	45 478	71 309	23 267	148 795
Events, <i>n</i>	74	609	1419	621	2723
Nonevents, <i>n</i>	8667	44 869	69 890	22 646	146 072
Proportion of women with events	0.9	1.3	2.0	2.7	1.8
>2.5%					
Women, <i>n</i>	90	2672	15 891	44 452	63 105
Events, <i>n</i>	0	38	340	1467	1845
Nonevents, <i>n</i>	90	2634	15 551	42 985	61 260
Proportion of women with events	0.0	1.4	2.1	3.3	2.9
Total					
Women, <i>n</i>	249 959	186 106	124 420	68 744	629 229
Events, <i>n</i>	1761	2390	2513	2120	8784
Nonevents, <i>n</i>	248 198	183 716	121 907	66 624	620 445
Proportion of women with events	0.7	1.3	2.0	3.1	1.4

Population

- Regular v. Augmented Screening
- 629,229 women in each group
- 8,784 breast cancer cases anticipated

Regular Screening

- N=629,229
- 211,900 have risk $> 1.67\%$
have some kind of intervention
- 4216 cancers in $< 1.67\%$
- 4568 cancers in $> 1.67\%$

Augmented Screening

- N=629,229
- 193,164 have risk > 1.67%
have some kind of intervention
- 4151 cancers in < 1.67%
- 4633 cancers in > 1.67%

Effect of Screening

- 65 additional cases would get intervention
- With 50% benefit of intervention
- 32.5 cases of cancer averted
- Net efficacy: $33 / 8784 = 0.4\%$ of cases averted
- Population RR = 0.996

Case Reclassification

- 2 x 2 table using 1.67%
- Net case reclassification is 0.007
- $TPF_{std} = 4568/8784 = 0.52$
- $TPF_{aug} = 4633/8784 = 0.527$
- Difference in TPF = 0.007

Net Reclassification

- Consider 2 x 2 classification
- NRI_{case} is difference of TPF
- $NRI_{control}$ is difference of FPF
- $RR_{pop} = 1 - (NRI_{case}) * RR$
 $0.996 = 1 - (0.007) * 0.5$
- 100% prevention only $RR_{pop} = 0.993$

Public Health Impact

- 65 cases prevented
- NNT = 2,971
- Treated standard: 211,900
- Treated augmented: 193,164
- Reduces treated by 3% in non-cases

Odds Ratio

- Risk factor may have elevated OR
- Individual risk is modified by risk factor
- Population risk may not be greatly modified
- Especially true if risk factors cluster
- Both embody some level of truth

C-statistic

- Very difficult to budge
- Measure pure ability to classify
- However, strict classification is rarely of interest
- More interested in risk stratification

Net Reclassification

- Net reclassification tied to cutpoints
- Map to clinical decision rule
- Has correspondence to hypothetical clinical trial
- Devil is in the details:
where and how many cutpoints

Summary

- Must balance false positives and false negatives
- Utilities may be very different for different people
- Attempt to relate to clinically relevant measures: individual or population level
- NRI: population level effects